Syntomycin 10% liniment for external use 25 g

Infected wounds in the II phase of the wound process (absence of pus, necrotic tissues); long-term non-healing trophic ulcers; burns of 2nd-3rd degree.

For external use.
After surgical treatment of wounds and burns, synthomycin liniment is applied directly to the wound surface, after which a sterile gauze dressing is applied, or the synthomycin liniment is applied to the dressing material and then to the wound. Tampons with liniment are loosely packed into the cavities of purulent wounds after surgical treatment, and gauze tampons with synthomycin liniment are inserted into fistulous tracts.
In the treatment of wounds and burns in the second phase - once every 1-3 days depending on the dynamics of wound healing.

Composition per 1 g:
Active ingredient: chloramphenicol [D,L] (syntomycin) - 100 mg;
Excipients: castor oil, emulsifier No. 1, sorbic acid, ethanol 96%, sodium carmellose, purified water.

Homogeneous liniment of white or white with a yellowish tint color with a faint characteristic odor.

Individual intolerance, suppression of bone marrow hematopoiesis, acute intermittent porphyria, glucose-6-phosphate dehydrogenase deficiency, liver and/or kidney failure, skin diseases (fungal infections, psoriasis, eczema), pregnancy, lactation period, neonatal period (up to 4 weeks). Due to the lack of osmotic activity (base: oil, emulsifier), it is not recommended to use in the first phase of the wound healing process (abundant purulent discharge, pronounced tissue swelling, pain, and presence of necrotic tissues).

During treatment, systematic monitoring of the peripheral blood picture is necessary. No adverse effects on the fetus have been identified during pregnancy and breastfeeding. When applied to extensive surfaces while simultaneously consuming ethanol, disulfiram-like reactions may occur (skin flushing, tachycardia, nausea, vomiting, reflex cough, seizures).
Impact on the ability to drive a vehicle and perform tasks requiring high speed of mental and physical reactions
Not identified.

Possible allergic reactions: skin rash, angioedema. Hematological side effects: rarely - reticulocytopenia, leukopenia, granulocytopenia, thrombocytopenia, erythropenia, aplastic anemia, agranulocytosis.

No cases of overdose have been reported with the use of the medication.

When used simultaneously with erythromycin, clindamycin, or lincomycin, a mutual weakening of action may occur due to chloramphenicol potentially displacing these drugs from their bound state or preventing their binding to the 50S subunit of bacterial ribosomes. It reduces the antibacterial effect of penicillins and cephalosporins.

The active ingredient of the product is chloramphenicol - a broad-spectrum antibiotic with high antibacterial activity against the causative agent of wound infections and various forms of purulent-inflammatory processes. Chloramphenicol is a bacteriostatic antibiotic that disrupts the protein synthesis process in microbial cells (due to its high lipophilicity, it penetrates through the bacterial cell membrane and reversibly binds to the 50S subunit of bacterial ribosomes, which results in the inhibition of amino acid transfer to growing peptide chains, leading to the disruption of peptide bond formation and protein synthesis). It is active against most strains of penicillin-resistant gram-positive and gram-negative microorganisms, as well as those resistant to tetracyclines and sulfonamides. It promotes the cleansing and healing of burn wounds and trophic ulcers, and accelerates epithelialization. Pharmacokinetics: the extent of absorption into the systemic circulation after application of the product to the skin, wounds, or mucous membranes is unknown.

The degree of absorption into the systemic circulation after application of the drug to the skin, wounds, or mucous membranes is unknown.